IPHA

Innate Pharma S.A.

NasdaqGSUSDEQUITY DELAYED

2.26

▲ 0.17 (8.13%)

MARKET · —

Price

Open

2.22

Prev close

2.09

Day high

2.30

Day low

2.20

Volume

43.79K

Market cap

—

P/E (TTM)

—

52W range

1.17 – 2.71

Trailing performance

Price return · vs SPY

Returnvs SPY

+3.67% +5.0%

+28.41% +24.7%

+14.72% +11.6%

+39.51% +28.4%

YTD

+29.14% +16.9%

+1.35% -18.7%

-22.34% -96.5%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

2.24

+1.10% from price

SMA 20

2.00

+13.25% from price

SMA 50

1.88

+20.32% from price

SMA 100

1.74

+29.62% from price

SMA 200

1.73

+30.42% from price

EMA 12

2.13

+6.34% from price

EMA 26

2.01

+12.26% from price

EMA 50

1.91

+18.12% from price

RSI (14)

59.2

Neutral

MACD (12,26,9)

0.11

Hist 0.01

ATR (14)

0.24

10.40% of price

Realised vol 30D

106.5%

Annualised

Bollinger upper

2.52

20, 2σ

Bollinger lower

1.47

20, 2σ

50 / 200 cross

Golden

1.88 vs 1.73

Trend bias

Above 200

+30.42%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.54

More volatile than market

Correlation to SPY

0.20

Largely independent

Realised vol 30D

106.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-50.8%

Peak to trough

Max drawdown 5Y

-85.6%

Peak to trough

ATR 14

0.24

10.40% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 2.26

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

IPHA · links out to the publisher

Innate Pharma SA (IPHA) (Q2 2026) Earnings Call Highlights: Strategic Partnerships and Pipeline ... GuruFocus.com · 5d ago Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative Simply Wall St. · 8d ago Innate Pharma Secures €30M, Extends Cash Runway Into 2028 MarketBeat · 8d ago Innate Pharma Announces Conference Call and Webcast Business Wire · 8d ago Leerink Partners Upgrades Innate Pharma to Outperform From Market Perform, Adjusts PT to $4 From $3 MT Newswires · 11d ago Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III Pharmaceutical Technology · 12d ago Innate Pharma, Sobi Partner on Late-Stage Study for Lacutamab MT Newswires · 12d ago Innate Pharma, Swedish Orphan Biovitrum Partner to Advance Phase 3 Lymphoma Drug; Shares Surge Pre-Bell MT Newswires · 12d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.